JAGX Jaguar Health, Inc.

Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), said an abstract covering preliminary results from an ongoing study of crofelemer in adults with short bowel syndrome with intestinal failure has been accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting. ACG 2026 is scheduled to take place from October 9 to October 14 in Nashville, Tennessee.

Jaguar Health is surging on a float so thin that a handful of trades can swing the price wildly, while a rare pediatric disease program edges closer to a pivotal regulatory filing that could either validate the rally or expose how fragile it really is.

Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.

Jaguar Health and Viking Therapeutics are both sinking Wednesday morning, but the forces behind each drop point in completely different directions, and the broader biotech sector is barely flinching.

Jaguar Health aims to file for approval of its Crofelemer powder treatment for pediatric MVID in mid-2027.

The non-prescription digestive-support product extends Jaguar Health’s Neonorm franchise into the companion-animal market, with additional online and retail distribution expected shortly. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) has launched Neonorm Dog on Amazon as part of the commercial rollout of its new non-prescription animal-health product.

Jaguar Health Inc (JAGX) reports groundbreaking MVID trial results and secures $18M in non-dilutive capital via FuturePak deal, despite a 60% revenue decline.